MAGE

Scientists Rapidly Advancing Cancer Vaccine Prospects Using Same Technology as Covid-19 Shots

Retrieved on: 
Friday, September 17, 2021
Cancer, University, BNTX, Antigen, AZN, Technology, AstraZeneca, CAGR, Quality control, Immune system, Protein, Patient, MAGE, Pembrolizumab, Patent, BioNTech, COVID-19, GMP, GLP, MRNA, Safety, Moderna, Infection, News, CSE, Vaccine, CureVac, NASDAQ, CVAC, Merck, Boehringer Ingelheim, Large-cell lung carcinoma, COTA, NSCLC, Partnership, CMO, RNA transfection, PCV, Frustration, Eye, Time, SE, Research, Pharmaceutical industry

VANCOUVER, British Columbia, Sept. 17, 2021 /PRNewswire/ -- USA News Group  -  Using the same technology as their Covid-19 shot, scientists behind the University of Oxford and AstraZeneca PLC (NASDAQ:AZN) are getting closer to developing a therapeutic cancer vaccine, based on promising animal studies results. Based on the rapidly accelerating development of Covid-19 tech, expectations are rising in the field of oncology to keep pace, with a COTA survey reporting two-thirds (66%) of cancer patients and their close family members reporting disappointment or frustration with the progress of investigational cancer treatments. Thankfully, AstraZeneca isn't the only group in this fight, with several promising developments coming from other biotech firms, such as BioVaxys Technology Corp. (CSE:BIOV) (OTCQB:BVAXF), BioNTech SE (NASDAQ:BNTX), CureVac N.V. (NASDAQ:CVAC), and Moderna, Inc. (NASDAQ:MRNA).

Key Points: 
  • As well, as BioElpida is advancing preparations for GMP manufacturing of BVX-0918A, the preparation of the new manufacturing facility is ongoing and on schedule.
  • "This major step is essentially a 'dry-run' for manufacturing the vaccine and preparation for GMP production,"said BioElpida President Gilles Devilliers.
  • Researchers behind the AstraZeneca PLC (AZN) candidate have designed a two-dose cancer vaccine using the same viral vector technology used in its Covid-19 treatment.
  • According to analysts , the mRNA cancer vaccine market is expected to boom to $127 billion at a CAGR of +28% between 2021-2028.

Vilcek Foundation awards $600,000 to immigrant professionals in the United States

Retrieved on: 
Tuesday, September 7, 2021

The Vilcek Foundation announces the recipients of the 2022 Vilcek Foundation Prizes, totaling $600,000.

Key Points: 
  • The Vilcek Foundation announces the recipients of the 2022 Vilcek Foundation Prizes, totaling $600,000.
  • Each year, the foundation awards three major prizes: the Vilcek Prize in Biomedical Science, the Vilcek Prize in the Arts and Humanities, and the Vilcek Prize for Excellence.
  • The foundation also awards six Vilcek Prizes for Creative Promise to immigrant professionals whose early-career work represents a significant contribution to their field, and demonstrates exceptional insight or innovation.
  • "The 2022 Vilcek Foundation Prizes celebrate outstanding immigrant professionals in biomedical research and technology, and in dance and movement arts."